Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL627898 | 0.90 | GSK3B (0.52) | GSK3B | |
| SCHEMBL4480331 | 0.84 | GSK3B (0.61) | GSK3BCYP1A2 | |
| SCHEMBL4479022 | 0.83 | GSK3B (0.71) | GSK3BCYP1A2 | |
| SCHEMBL4502574 | 0.81 | GSK3B (0.57) | GSK3BCYP1A2 | |
| SCHEMBL4489897 | 0.81 | HDAC1 (0.63) | GSK3B | |
| SCHEMBL627841 | 0.81 | GSK3B (0.63) | GSK3B | |
| SCHEMBL12899672 | 0.79 | GSK3B (0.60) | GSK3B | |
| SCHEMBL4480272 | 0.79 | HDAC1 (0.66) | GSK3B | |
| SCHEMBL4484161 | 0.79 | AAK1 (0.64) | GSK3BCYP1A2 | |
| SCHEMBL4490777 | 0.78 | HDAC1 (0.65) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1820503-B1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA SRL (IT) | 2012-02-22 | — | — | EP | disclosed |
| EP-1432416-B1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER ITALIA SRL (IT) | 2011-01-19 | — | — | EP | disclosed |
| US-7511136-B2 | Aminoindazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-03-31 | — | — | US | disclosed |
| EP-1820503-A2 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | Pfizer Italia S.r.l. (IT) | 2007-08-22 | — | — | EP | disclosed |
| CN-1556702-A | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | — | 2004-12-22 | — | — | CN | disclosed |
| US-20040254177-A1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2004-12-16 | — | — | US | disclosed |
| EP-1432416-A1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pharmacia Italia S.p.A. (IT) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003028720-A1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254177-A1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | MAP3K15, MAP3K3, MAP3K5 | GSK3B 143/4885CYP1A2 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.